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Abstract:  
Cardiovascular atherosclerotic and ischemic diseases constitute the leading cause of morbidity and 
mortality throughout middle- and high-income countries. More efficient preventive and regenerative 
therapeutic strategies are therefore urgently needed. The repeated finding that putative “endothelial 
progenitor cells” (EPCs) can efficiently promote angiogenesis and restore perfusion of ischemic tissues 
has provoked a wealth of studies evaluating and developing their therapeutic potential. In the present 
review, we discuss the growing knowledge about various distinct cell populations which have been 
collectively termed “EPCs”, including myeloid cells and progenitor cells of different origin. We also 
present clinical studies aiming to examine their therapeutic potential for cardiovascular disease. In 
addition, we will discuss recent insights into mechanisms leading to dysfunction of “EPCs” in 
cardiovascular disease. Those findings may help to optimize autologous cell-based treatment 
approaches, as well as to establish cellular dysfunction itself as an interesting novel therapeutic target.  
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1. INTRODUCTION  
Impaired endothelial cell integrity and function play a major role in atherosclerosis, as well as in 
ischemic cardiac and peripheral disease. The need to maintain endothelial function and integrity 
throughout life is challenged by the constant exposure of the endothelium to recurring noxious 
influences, such as cigarette smoking, dyslipidemia and hyperglycemia that induce increased 
endothelial reactive oxygen species (ROS) generation ([1, 2], reviewed in [3]).  
Cardiovascular pathologies may result from deterioration of endothelial function and integrity in both, 
the microcirculation as well as the macrocirculation. As microvascular endothelial cells (EC) become 
dysfunctional and apoptotic e.g. in patients with diabetes mellitus (DM) or hypertension, capillaries in 
vital organs as well as in limbs dissociate, which results in inadaequate tissue perfusion and impaired 
wound healing [4, 5]. In the macrovasculature, endothelial dysfunction i.e. impaired endothelial nitric 
oxide (NO) availability, is a hallmark of early atherosclerosis. Today’s conception is that constitutive or 
recurring endothelial activation, in particular in regions of oscillatory shear stress or turbulent blood 
flow, is characterized by upregulation of adhesion molecules, loosening of EC-EC junctional bonds, 
increased generation of ROS and impairment of NO availability, which finally induce and maintain an 
increased inflammatory state of the vascular wall. As a result, the enhanced recruitment of leukocytes 
and inflow of plasma lipids and lipoproteins into the sub-endothelial space promote the formation of 
atherosclerotic plaques [6]. Progressing plaque growth, together with plaque rupture or erosion and 
thrombosis induce acute vessel occlusion, such as in myocardial infarction (MI) or ischemic stroke. 
While acute treatment focuses on the restoration of tissue perfusion e.g. by thrombolysis or 
percutaneous intervention, the induction of reparative angiogenesis i.e. the growth of new 
microvessels into the tissue at need, is considered a promising strategy to confine post-infarction 
cardiomyocyte (CM) loss. This strategy crucially relies on the endothelium as a main player.  
Although today we have several pharmacological tools available to combat the progression of CVD and 
to enhance survival following acute cardiovascular events, a true regression of atherosclerosis as well 
as cardiac repair after MI or in ischemic heart disease are not sufficiently achieved by currently 
established treatments. Therefore, different cell-based therapies i.e. transplantation of immature cell 
types, such as stem and progenitor cells (S/PC) have been investigated for ischemic organ or tissue 
repair with great enthusiasm [7]. While the initial high hopes placed in this treatment have not yet 
been clearly fulfilled, we have gained first clinical experience, mostly with autologous bone marrow 
cells (BMC), including the establishment of safety of the procedure and the achievement of a 
significant, though rather small improvement of cardiac function after an acute MI. We have also 
achieved a better understanding of the cellular and molecular mechanisms underlying the action of 
various cell populations, including the so-called “endothelial progenitor cells” (EPC). As described 
below, this term has been used for several different cell populations, and not all of these are “true” 
endothelial progenitors (in the sense that they differentiate into mature endothelial cells in vivo), but 
may rather promote endothelial growth in a paracrine fashion. The field is now advancing towards an 
optimization of treatment protocols, which are better adjusted to the individual pathology and 
characteristics of the donor/recipient, and is focusing on overcoming important limitations of cell-
based therapies, including ways to establish ex vivo technologies to improve the functional capacity of 
patient-derived autologous cells.  
2. WHAT ARE “ENDOTHELIAL PROGENITOR CELLS”?  
In the early 1990s, endothelial cell progenitors were largely examined in embryonic development of 
the cardiovascular system and the term was applied to cells with a low degree of differentiation, but a 
high potential to differentiate towards endothelial cells. These cells were also termed angioblasts [8]. 
In 1997, Asahara and colleagues reported the existence of circulating cells with endothelial lineage 
potential - i.e. putative “endothelial progenitor cells” – in the postnatal setting i.e. within enriched 
CD34+ cell fractions obtained from the peripheral blood of human donors [9]. Despite the in vitro 
endothelial differentiation potential of postnatal CD34+ cells, only few of these cells or their progeny 
were detected at sites of neovascularisation after transplantation in in vivo ischemia models. In 
comparison, the observed functional effects (considerably increased neovascularization and blood 
flow) were beyond what could be expected from differentiated progenitor cells replacing lost EC, or 
generating new ones [10]. Further findings underlined the importance of paracrine effects of the 
putative “EPCs” for the observed functional improvement i.e. reduction of ischemia [11-13].  
Methodological and terminological inconsistencies have contributed to the fact, that severeal different 
cell populations have been termed “endothelial progenitor cells”: After the late nineties, so-called 
“EPCs” were obtained by subjecting unsorted peripheral blood mononuclear cells (PBMC) to adherence 
culture in endothelial growth medium immediately, omitting the CD34+ enrichment step [14]. The 
resulting cells had both, monocyte markers such as CD14, and endothelial markers such as VE-cadherin 
[14]. Later work verified the myeloid identity of the outgrowing cells [11, 15]. However, the majority of 
the community adopted the term “endothelial progenitor cells” for these PBMC-derived cells and also 
discussed their possibilities in this context, fuelled by the cells´ therapeutic capabilities which was by 
now beginning to be verified in human patients [14, 16, 17].  
Minute characterization of PBMC-derived cells has established that two - still heterogeneous – 
populations of cells with angio-supportive characteristics can be obtained from adult peripheral blood: 
“early EPCs” or “early outgrowth cells” (EOC), which adhere to fibronectin-coated plastics within 4-7 
days, at which time colony-like cell clusters can be observed; and “late EPCs”, also termed “endothelial 
colony- 
forming cells (ECFC)”, which adhere to collagencoated plastics faster (within two days), but take longer 
(two to three weeks) to form proliferating colonies [13]. EOC (or “early EPCs”) mainly consist of 
monocytic cells, which do not give rise to mature EC, but integrate into the subendothelial space of an 
injured host vessel wall after transplantation - a feature that reminds of resident “patrolling” monocyte 
subtypes [18, 19]. In contrast, ECFC (or “late” EPCs) contain only minimal amounts of myeloid cells, 
while a larger protion of them can differentiate into cells of endothelial phenotype [12, 13, 20, 21]. 
Similar functional characteristics seem to apply to CD34+ vs. CD14+ circulating cell types, freshly 
isolated from the circulating blood [22]. Of note, the role of monocytes indeed seems to be 
fundamental to the architecture of newly generated vascular networks, due to their ability to form 
linear and branched structures in three-dimensional matrix and to interact with various cell types of 
vascular and non-vascular identities, thus guiding the course of the neovessel [23].  
Apart from circulating cells, derived from the bone marrow (BM) or other organ stem cell niches, 
various types of vascular resident S/PC have been identified. They may contribute to angiogenesis, 
population of vascular grafts by recipient cells, and possibly also to vessel wall remodelling and 
atherosclerosis [24-28]. Their role in physiology and pathophysiology seems to be underestimated as 
far as now, especially in the context of stent healing or in-stent restenosis [29].  
For this review, the term “endothelial progenitor cell” will be applied as a generic term including “true” 
endothelial progenitors - circulating and resident - which are able to give rise to endothelial cells as 
well as to myeloid EOC, that rather act in a paracrine fashion on the endothelium. For clinical studies, 
we will largely refer to experience with autologous BMC, although they clearly constitute a 
heterogeneous cell population containing mature cells in addition to mesenchymal and hematopoietic 
progenitors (MSC, HSC, respectively).  
This concept reflects the two directions in which research on “EPCs” progresses: (1) the ongoing search 
for the "true" angioblast/endothelial progenitor cell, driven by the motivation to understand 
underlying cellular processes of vascular pathologies and regeneration, as well as to identify a defining 
set of antigenic markers [30], and (2) the clinically motivated search for the therapeutically most 
efficient cell(s), not necessarily willing to await improved mechanistic understanding, but with the 
chance to speed up the development of potentially efficient therapies. Yet, mechanistic understanding, 
including cellular identity, is critical to clinical application, in order to improve efficiency and safety, 
while economic, ethical and logistic aspects might hinder the transgression of specific cell types into 
the clinical setting, which are nevertheless highly suited in in vitro and pre-clinical studies, such as 
embryonic SCs.  
 
3. THERAPEUTIC POTENTIAL AND NON-TARGET EFFECTS OF “ENDOTHELIAL 
PROGENITOR CELLS”  
The contribution of different types of endothelial supportive cells to tissue healing and/or regeneration 
varies between individual pathological settings. Maintenance or restoration of a confluent, non-
activated endothelial layer requires long-acting mechanisms considering also the delicate interactions 
between various cell types. Monocytes/EOC via their capacity to phagocytose dysfunctional or dying 
cells, to export cholesterol from the vessel wall, and to secrete distinct spectra of cytokines, play an 
important role here [11-13, 31, 32]. In contrast, regeneration of the postinfarction myocardium, again 
crucially involving the phagocytotic and paracrine activity of monocytes, progresses in two distinct 
stages: first, a fast “clean-up” of dead and dying cells, and later on, the stimulation of repair i.e. 
angiogenesis and thereby enhancement of tissue perfusion [33, 34]. Other EOC- and BMC-mediated 
mechanisms include remodelling of the extracellular matrix and possibly the enhancement of 
cardiomyocyte (CM) survival and functionality by paracrine mechanisms [35-39].  
The qualitative and quantitative composition of the “EPC”- or BMC-derived secretome crucially affects 
short and long-term therapy success. In general, cytokines secreted by the recruited leukocytes are 
considered to beneficially impact on infarct size and cardiac function after MI [40]. On the other hand, 
leukocyte-derived cytokines have been associated with post-MI microembolisation and may affect 
vessel maturation [41-47]. Following MI, the time interval between the acute event and cell application 
is characterized by alterations in milieu conditions i.e. a high inflammatory load within the first week 
followed by a more repair-promoting milieu at later stages [33, 34]. BMC transplantation after the first 
week post-MI could therefore be more effective [48], a concept which is currently examined 
prospectively in clinical trials in patients after MI (SWISS-AMI, TIME).  
As “EPCs” may support vascularisation of an ischemic tissue, so they may do with a (silent) tumour, 
potentially facilitating tumour growth [49, 50]. In this context, the risk of de novo tumour 
formation/leukaemia induction, which has been observed after transplantation of foetal stem cells or 
cord blood cells [51, 52], might be reduced by using committed progenitor cells, or differentiated 
(autologous) adultderived cells [53, 54]. Although angiogenesis in the ischemic heart or peripheral 
limbs might be a therapy target of BMC/”EPC” transplantation, angiogenesis at developing or mature 
plaques is unwanted, as it may confer plaque instability [55-57]. Even in the absence of noticeable 
angiogenesis, recruited HSC/myeloid EOC may facilitate intima thickening, destabilize plaques or 
promote calcification [58-61]. Likewise, circulating or resident progenitor cells may contribute to 
intima thickening [62]. Although, in the current clinical trials of BMCs in patients after MI, no safety 
concerns have been raised, this aspect always needs to be taken into account for cell-based therapies.  
Immunological aspects hinder the usage of allogenic donor cells, while embryonic stem cells -although 
harbouring favourably high differentiation potential and low immunogenic risk - are potentially 
tumourigenic and raise ethical concerns, further aggravated by the opposition of high numbers of 
potential recipients and the low number of in-hospital abortions. From ethical, economical and safety 
aspects, autologous cell sources therefore remain as the most practicable cellular source. Indeed, cells 
with angiogenic/vascular potential have been detected even in CVD patients, albeit cellular 
functionality negatively correlates with cardiovascular risk, leaving the least potent cells to the patients 
who would need the most functional ones [63-65]. Two strategies can be derived from those 
considerations: the protection of stem cell niches throughout life needs to be addressed prospectively 
[66]. For the individual patient in need for treatment, ex vivo “priming” or engineering of autologous 
cells might provide more efficient approaches in the near future. Various strategies have been devised 
towards that end, including improvement of isolation and storage protocols for the selection of the 
most efficient cell type and their and functional preservation [67, 68] as well as ex vivo pharmaceutical 
pre-treatment or genetic engineering of cells prior to re-implantation. Improving the number of cells to 
reach the target tissue and to persist there e.g. by optimizing the route of transfusion or accompanying 
pharmacological treatment (e.g. CD26 inhibitors), might further improve efficiency. Below, we will 
discuss distinct strategies to employ endothelial growth promoting cells in distinct pathological 
situations.  
3.1. “EPCs” to Treat Microvascular Dysfunction and Rarefaction  
Microvascular rarefaction i.e. the reduction and loss of a functional network of capillaries normally 
ensuring organ perfusion, likely contributes to different forms of cardiomyopathy, including ischemic 
or hypertensive cardiomyopathy and diabetic cardiomyopathy. Deteriorating microvasculature looses 
pericyte coverage and assumes a tortuous phenotype with discontinuous endothelium (Fig. 1) [69]. 
Although at the first glance paradoxical, the loss of capillaries in heart, kidney and peripheral tissues 
shares some molecular and cellular mechanisms with diabetic retinopathy, such as increased capillary 
permeability and tortuosity (reviewed in [70]).  
The demonstration of the pro-angiogenic potential of “EPCs” has therefore raised hopes for a novel 
treatment strategy, especially in those patients who do not respond to other modes of therapy [16]. 
However, cellular functions of “EPCs” are severely affected i.e. in diabetic patients and smokers, thus 
potentially limiting the efficiency of autologous cell transplantation [64, 65]. Ex vivo modification of 
cellular function prior to re-introduction (Table 1) might therefore harbour specific benefits for 
patients with an impaired “EPC” function. As an example, the overexpression of platelet-derived 
growth factor (PDGF), a mediator of pericyte-EC interaction during microvessel stabilization, has been 
proposed. Interestingly, ex vivo PDGF treatment of human CD34+ progenitor cells enhanced their 
homing in a diabetic mouse model and promoted in vitro the emergence of adherent cells/clusters that 
expressed the endothelial markers VE-cadherin and CD31 [71]. Ex vivo overexpression of growth 
factors (e.g. vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF-1)) [72, 73], 
oxidative defence effectors (e.g. manganese superoxide dismutase), endothelial nitric oxide synthase 
(eNOS), or PPAR.. activators served to improve cellular functions in in vitro studies and animal models 
[72-76]. Transfer of these experimental approaches into the clinical setting might come closer with the 
development of safer vectors and the availability of first results from clinical trials employing direct and 
cell-mediated gene therapy (reviewed in [77, 78]). Alternatively, biodegradable matrices could be 
adopted as a means for time and dosage-dependent release of mature proteins e.g. for topical 
application in diabetic wound healing [79]. Furthermore, systemic effects are exerted by lifestyle 
approaches, such as physical exercise training or flavonoids in certain foods (tea, red wine, chocolate), 
as well as drugs with pleiotropic actions. Especially statins have been shown to be effective in 
improving “EPC” availability and function via activation of the PI3K/Akt/eNOS pathway, besides potent 
anti-inflammatory effects and blockade of the ratelimiting enzyme of cholesterol synthesis, HMG-
CoAreductase [80-82].  
The kallikrein-kinin-system has gained attention for its role in regulating angiogenesis, as well as 
vascular stabilization [83-85]. Cellular players are mature cells of the vasculature, such as EC or SMC, 
but also EOC, as well as individual progenitor and leukocyte subtypes, which regulate angiogenesis in a 
paracrine manner. In a non-diabetic mouse model, expression of the kinin B2 receptor was necessary 
for the recruitment of progenitor cells to ischemic tissue and initiation of capillary growth and 
reperfusion [86]. In vitro, EOCs migrated towards the B2 receptor ligand bradykinin (BK) and were 
enriched out of the heterogeneous PBMC by using BK as a chemoattractant. Progenitor cells from 
patients with CVD could not be enriched by BK-induced migration [86]. Interestingly, progenitor cells 
and monocytes from young type 1 diabetic patients without CVD retained B2 receptor expression and 
BK-induced migration, while individual B2 receptor-mediated cellular functions, such as NO generation, 
were impaired [87]. Uncoupling of the B2 receptor from downstream signaling was associated with 
reduced expression of tissue kallikrein, a protease mediating kinin generation and matrix degradation, 
leading to impaired invasive capacity of EOCs from type 2 diabetic patients [88]. Consequently, ex vivo 
overexpression of both, kallikrein and the B2 receptor, in diabetic EOC did restore invasive capacity 
[88]. While interactions between the members of the kallikrein-kinin system may be complex and 
simple overexpression of one component might not suffice to restore angiogenesis in certain 
pathologies [88, 89], combinatory treatment, together with re-coupling of eNOS, might enhance EOC 
pro-angiogenic capacity.  
Maturation of the nascent vascular network i.e. the recruitment of pericytes and SMC to provide 
stability and reduce permeability is crucial to ensure functionality of newly generated vasculature [90]. 
To achieve both, initiation of angiogenesis and subsequent pericyte recruitment, VEGF and PDGF have 
been successfully applied as dual gene therapy in various animal models [91, 92]. Recent work 
furthermore indicates an additional role of the kinin B2 receptor in vessel maturation by pericyte/SMC 
recruitment [84]. The intrinsic capacity of “EPCs”/EOCs to counteract capillary permeability by 
stabilizing tight junctions, as was shown recently for myoeloid multipotent progenitor cells, might be 
enhanced by tailored modification of autologous “EPCs”' paracrine activity prior to reintroduction e.g. 
by cotransfection with different growth factor genes [93].  
Besides 'classical' paracrine substances, further mediators of endothelial function, supplied by “EPCs”, 
as well as alternative routes of delivery have been identified. Interesting novel data have indicated that 
actively shed membranous vesicles, depending on their size classified into microparticles (MP), 
exosomes, or microvesicles, may carry soluble proteins, membrane proteins, lipids and nucleic acids, 
thus mediating communication between the cell of origin and the target cell over variable distances 
[94-98]. Exogenously modified “EPC”, which shed MPs, or the “EPC”-derived MPs themselves are 
therefore considered promising tools for targeted drug delivery [99]. This principle could be extended 
to ex vivo engineering of “mother cells” shedding MPs containing a desired protein or microRNA 
profile. The cells would then be available for producing multiple doses of paracrinally active 
“conditioned medium” to be transplanted during several treatment sessions, which might increase 
efficiency of the therapy [100].  
Therefore, by their intrinsic paracrine activity, “healthy” EOCs might counteract the destabilization of 
microvascular networks, as well as support the re-constitution of a mature, stable network of new 
capillaries (Fig. 1). Ex vivo engineering or pre-conditioning of patients autologous EOCs (i.e. by 
overexpression of pro-survival factors and/or chemoattractants, or exposure to survival-promoting 
drugs (Table 1)) prior to transplantation might be helpful, not only to promote angiogenesis, but also 
to enhance stability of newly generated or pre-existing micro-vessels.  
3.2. Potential of “EPCs” as a Therapeutic Strategy for Macrovascular Disease  
As for the establishment of a functional neovasculature, the interplay between endothelial and sub-
endothelial cells of the vascular wall is critical for the maintenance of macrovascular function. During 
life, various factors, such as circulating lipids and glucose, turbulent flow due to vascular geometry, and 
inflammatory cells activated by environmental toxins, add up to establish permanently inflamed areas 
of the vascular wall, predominantly at bifurcations. This is followed by intima thickening due to the 
immigration of leukocytes from the blood and SMC from deeper layers of the vessel wall. Inflammation 
is further promoted by leukocytes entering the plaque via vasa vasorum. The loss of endothelial 
function and integrity plays a crucial role in atherogenesis: Endothelial-derived NO generation, 
important for controlling SMC relaxation and proliferation, is reduced and the tight coupling of 
endothelial cells through junction molecules, as well as low expression of adhesion molecules, are 
reverted. In consequence, plasma proteins can leak into the subendothelial space, followed by 
leukocytes which invade the vessel wall. Therefore, the reconstitution of endothelial confluence and 
quiescence is regarded key in prevention and halting of atherosclerosis, while its reversal might be 
achieved by enhancing reverse cholesterol transport e.g. by HDL [101]. Towards this end, functionality 
and survival of EOC when exposed to the pro-apoptotic conditions within the inflamed vessel wall are 
critical for effectively counteracting atherosclerosis [102].  
The role of “EPCs” in counteracting, but also potentially in promoting atherosclerosis seems to be 
conveyed mainly by their paracrine action Fig. (2). They can attenuate vascular inflammation e.g. by 
interleukin-10 secretion, support endothelial cell turnover e.g. via NO generation or secretion of 
interleukin-8, hepatocyte growth factor or VEGF [11], or by promoting reverse cholesterol transport 
[103]. Special attention has been given to the capacity of EOCs for NO generation, which is considered 
a hallmark of their functional capacity [19, 104-106]. Indeed, “EPC” may loose the capacity for NO 
generation well before the onset of vascular disease in persons with increased risk, such as diabetes 
mellitus or pre-hypertension [19, 87]. Paracrine dysfunction of “EPC” in persons with enhanced 
cardiovascular risk (e.g. in smokers or diabetic patients) therefore may impair endothelial functions 
two-fold [107-109]. In the chronic setting, treatment options such as statins or exercise training, which 
can improve “EPC” paracrine actions in vivo without need of cell extraction, ex vivo modification and 
re-implantation, seem favourable, as drugs/lifestyle modifications can be applied over long time 
courses. In contrast, single cell transplantation treatments may only cover shorter time periods. 
However, cell-derived non-immunogenic products, such as microvesicles loaded with specific proteins 
or microRNA, might be suitable for repeated administration. Detailed investigation of microvesicle 
composition and the systemic effects exerted by individual microRNAs in CVD are therefore awaited 
with great expectations.  
As discussed elsewhere [110], percutaneous coronary intervention (PCI) induces severe damage to the 
endothelium i.e. endothelial denudation and stretching of matrix and underlying cell layers. The fast 
re-establishment of a confluent, quiescent endothelial layer is therefore accounted crucial for both, 
the attenuation of atherosclerosis, as well as the prevention of in-stent re-stenosis/thrombosis. 
Antibodymediated capturing of circulating CD34+ progenitor cells by implanted stents is currently 
followed as a potential strategy to promote endothelial healing after stent implantation [111, Current 
Vascular Pharmacology, 2012, Vol. 10, No. 1 113  
112]. Although safety and feasibility were suggested by several studies [113-115], higher rates of target 
vessel failure in patients receiving the “EPC-capture-only” stent were described for high risk lesions as 
compared to drug-eluting stents [116-121]. Therefore, a new generation of combined CD34+ attracting 
and drug-eluting stents is currently entering clinical trials (REMEDY, REMEDY-OCT) with the hope to 
achieve accelerated endothelial healing without increasing restenosis risk [122].  
While progenitor cells circulate in the blood only in low numbers, resident S/PC within adjacent 
vascular sections provide a more readily available source for re-population of vascular grafts, and 
possibly also for the reendothelialisation of stents or - with adverse result - intima growth [24, 25, 27, 
123, 124, 28]. Vascular resident S/PCs are positioned where they can rapidly provide support to 
damaged endothelium, but naturally they will be equally affected by blood-borne stressors, like 
inflammatory mediators increasing oxidative stress within the vessel wall, and may therefore suffer 
equally [125]. Consequently, bone marrow-derived progenitor cells, leaving their protective 
environment and entering the circulation, as well as vascularresident progenitor cells, will both be 
exposed to different factors, leading to cellular dysfunction [126].  
Statins achieve reduction of cholesterol levels by blocking HMG-CoA reductase, but they also activate 
the prosurvival Akt/eNOS pathway and skew EOC differentiation towards an repair-promoting 
phenotype [81, 127]. In the setting of stent implantation, concomitant statin therapy serves to 
accelerate re-endothelialisation and reduce intima thickening and thrombosis, improving survival after 
PCI [128-131]. Contributing to those effects might be the increased mobilization, as well as better 
homing characteristics of EOC and progenitor cells (Table 2) [127, 132, 133].  
Similarly, physical exercise training improves endothelial function in various physiological and 
pathological settings [134-136]. Exercise-induced effects are mainly ascribed to a systemic decrease of 
inflammatory agents, increased NO availability, downregulation of NADPH oxidase and upregulation of 
enzymes involved in antioxidative defence, but recent studies have also established higher numbers of 
circulating “EPC” [137-145]. Aortic valve stenosis represents another major cardiovascular pathology, 
which shares underlying mechanisms with atherosclerosis, such as leukocyte infiltration and 
endothelial deterioration, but calcification processes play a larger role than in atherosclerosis [146, 
147]. The progression of valve disease, characterized by EC loss, coincides with reduced survival and 
lower circulating numbers of “EPC” [148]. In this context, exercise training served to prevent aortic 
valve disease in a high-cholesterol induced mouse model of aortic valve disease, albeit only 
associations exist about the role of increased circulating “EPC” levels in the preservation of valve 
integrity [149]. In contrast to “EPC”, circulating cells which co-express osteocalcin and bone alkaline 
phosphatase, where identified to actively promote calcification hyperglycaemia and diabetes. Of note, 
those myeloid calcifying cells (MCC) were distinct from HSC/“EPC” according to their antigenic profile, 
including lack of CD34 expression [150]. However, the derivation of MCC from cultured PBMC, albeit 
under growth conditions distinct from EOC, suggests inclusion of MCC screening into the panel of 
characterization for EOC used for cell therapy. Lack of comparable characterization data currently 
precludes conclusions about the modulation of MCC in CVD and therapy strategies, such as statin 
treatment or exercise training [150, 151]. Resident vascular cells, such as SMC or pericytes might also 
differentiate into calcifying cells under certain milieu conditions [152]. Exercise-mediated maintenance 
or restoration of endothelial confluence - possibly via “EPC”-mediated mechanisms – might help to 
counteract this process [151].  
Much attention has been paid to the role of diet in retaining endothelial integrity and function, 
including unsaturated fatty acids, carbohydrate content and flavonoids [153-155]. Flavonoids present 
in red wine or cocoa, such as resveratrol or epocatechin, increase NO generation and reduce oxidative 
stress [156-158]. In vitro, as well as in pre-clinical and clinical studies, red wine, but not ethanol, 
enhanced “EPC” survival and increased vascularisation of ischemic tissues, mostly ascribed to NO 
mediated mechanisms [156, 158160]. In human CAD patients, intake of flavanol-rich cocoa increased 
NO production and the abundance of circulating “EPC” and improved endothelial function [161].  
In summary, EOCs as well as circulating and vascularresident S/PC may protect from atherosclerosis by 
preserving critical endothelial functions. Due to the chronic course of plaque development, the 
beneficial effect of single cell application might turn out to be limited. Furthermore, the availability of 
pro-atherosclerotic and calcifying elements within the heterogeneous populations of PBMC and BMC, 
bears the risk of advancing, rather than counteracting atherosclerosis. Therefore, modulating the 
systemic condition towards a reduction of inflammation and strengthening of antioxidative defence 
and promoting reverse cholesterol transport via systemic treatments holds greater promise. Resident 
or circulating “EPCs” will be among the cells benefiting, with niches protected, trafficking improved and 
differentiation driven away from pro-inflammatory directions.  
3.3. “EPCs” for Cardiac Repair  
The preservation of functional myocardium after AMI requires a fast restoration of reperfusion, as well 
as supplication of contractile and structural elements i.e. cardiomyocytes (CM) and fibrocytes. Due to 
their ability to enhance angiogenesis in ischemic situations, EOC, as well as various other BM-derived 
(stem) cell populations are regarded as promising tools for post-MI therapy [9, 162-164].  
While in individual clinical studies and meta-analyses a small, but significant benefit of cell therapy for 
left ventricular (LV) function has been suggested, not all trials were able to detect significant 
improvement in cardiac function [165171]. The differential outcome of those studies has been 
attributed to technical differences, especially isolation and transport/storage procedures, yielding cell 
populations with distinct composition and functional capacity, but also to the time point and mode of 
application, as well as patients characteristics [48, 67, 172].  
For practical reasons, most clinical studies have employed total BMC, whose cellular composition is 
rather mixed, including e.g. MSC, HSC, and stromal components. In consequence, various cellular and 
molecular mechanisms  
- in detail explored by using more defined cell populations in vitro or in animal models - might 
contribute to the observed salvage on myocardial function in patients receiving autologous BMC. “EPC” 
differentiation into functional CM is still debated and the main effect of BMCs in myocardial salvage 
after MI is likely held by promotion of angiogenesis [162, 173-184]. For MSCs contained within the 
BMC some cardiopoietic potential, as well as the capacity to affect conductance, have been suggested 
and appears to be promoted by a “cocktail” of cytokines [185, 186]. Few comparative clinical studies 
have investigated the relative potential of total BMC in comparison to more defined cell populations, 
with heterogeneous outcome. Similar efficiency was attested to EOC or CD34+CXCR4+ cells as 
compared to unselected BMC [164, 167, 187, 188]. To overcome low engraftment and in order to 
deliver a relevant number of efficient cells, high numbers of total BMC are usually transplanted. 
Thereby, higher absolute numbers of contaminating, potentially inflammatory cells might be 
coinjected, possibly impeding the healing effect and triggering adverse events [188, 189]. To further 
optimize the efficacy of cell engraftment after transplantation, various routes of cell delivery have 
been used, including intracoronary, direct intracardiac (surgical transepicardial or catheter-based 
transendocardial) or intravenous injection. The appropriate method likely depends on the clinical 
scenario (i.e. acute infarction vs. chronic ischemic disease) and on the cell types used. Some studies 
have suggested a higher cell retention rate after intramyocardial injection, which allows targetted 
delivery, aided by mapping systems [190]. However, cell retention is generally low: Even with direct 
intramyocardioal injection, only around 10% of the injected cells are retained within the first hour of 
transplantation, with a further decline over the next days [191, 192]. Several groups therefore 
currently focus on enhancing the retention of injected cells, including delivery of cells within matrices, 
improvement of the microenvironment (i.e. recapitulating “niche-like” conditions), and ex vivo cell 
modifications (e.g. induction of adhesion molecules, improvement of survival) [193-199].  
Recent meta-analyses suggest that transplantation of total autologous BMCs may improve LVEF, but 
not left ventricular remodelling, and their potency depends on the donor/recipient characteristics, 
with active smoking, male gender, age and diabetes negatively influencing efficiency [200203]. As 
donor and recipient necessarily are the same person, it is difficult in clinical studies to discern the 
impact of the milieu, the cells are exposed to after implantation, from intrinsic dysfunctions of the 
cells. In vitro studies and ex vivo analysis of transplanted cells indicate that both are relevant. 
Transplanted cells and their surroundings mutually interact, and therefore improving transplanted 
cells' function ex vivo (Table 1) together with pharmacological and/or lifestylebased lowering of 
systemic inflammatory status (Table 2) might be necessary to increase efficiency of autologous 
cellbased therapy after myocardial infarction.  
Myocardial remodelling after acute infarction is characterised by two distinct phases in short to mid-
term, with fibrotic processes stretching on to longer time periods [33, 204]. The mainly inflammatory 
conditions within the first week, characterised by apoptosis/necrosis and phagocytosis, in opposition 
to regenerative/angiogenic processes which occur during the following weeks, might serve to explain 
why cell application may be more effective in improving LVEF at ..6 days as compared to ..3 days after 
hospitalization [48]. After establishment of cardiomyopathy, injection of autologous BMC was still able 
to reduce infarct size and improve ventricular function [205]. Similar to other cell types, EOC or 
progenitors become dysfunctional and apoptotic when exposed to high levels of TNF-.. or IL-1.., 
conditions occurring immediately after aMI [206, 207]. Transplanted cells further suffer from the still 
ischemic conditions at the target site [208]. In contrast, inflammatory cytokines decrease in the second 
and third week after infarction, supporting “EPC” persistence. In the blood of patients successfully 
undergoing cardiac rehabilitation, increased availability of CD34+KDR+ PC was described, which 
correlated with systemic VEGF, IL-8 and IL-10 levels [209]. Therefore, conditions early after infarction 
appear to be detrimental to cell survival and function, explaining better effects with later time points 
of transplantation [48]. Vice versa, dysfunctional PC/EOC may also supply inflammatory cytokines, with 
adverse effects on myocardial healing and possible arrhythmogenic potential through paracrine 
stimulation of adjacent CM [185, 210]. Therefore, combination of cell application with statin therapy 
might yield synergistic effects, due to the systemic anti-inflammatory effects of statins, as well as 
specific effects on “EPC” survival and function e.g. differentiation [81, 206, 211]. Physical exercise, 
through multiple cellular and molecular mechanisms, including antioxidant and anti-inflammatory 
effects, is able to improve measures of cardiac function and geometry in heart failure patients and 
might also increase the success of stem cell transplantation [212]. In addition to their paracrine effects, 
electrophysiological alterations after cell transplantation have been debated and this depends on the 
cell type used [213]. Mechanistically, a lack of electrical coupling and distinct conductance 
characteristics between injected cells and the surrounding myocardium has been suggested to underlie 
arrhythmias, as suggested by various preclinical models i.e. co-culture and animal studies [214, 215]. 
Both, the lineage identity and stage of differentiation of the transplanted cell [216-218], as well as the 
position it is deposited at (surrounding myocardium viable or dead? [219]) affect electrical coupling to 
the host myocardium. For cardiopoietic cell types, the differentiation into various distinct CM lineages 
with individual action potential furthermore accounts for the occurrence of arrythmias [220]. However, 
the electrophysiological implications of cell therapy, as well as underlying cell-type specific 
mechanisms are not entirely clear today and several recent clinical studies observed either no signs for 
pro-arrhythmic effects or even report anti-arrhythmic effects of stem-cell based approaches [221-224].  
Due to their paracrine action, EOCs or other progenitor cell types, may affect all cell types in the 
vicinity, EC as well as CM, local SC niches or fibrocytes. In this context, their effect seems to be limited 
by the distance to the targeted CMs as well as by the length of their persistence [37, 225, 226]. Hence, 
higher numbers of recruited/persistent cells and uniform distribution along the target zone are aimed 
for in the clinical situation [227-231]. To ensure uniform high therapeutic quality of clinical stem cell 
therapy, optimized and standardized cell preparation, transport, and storage protocols need to be 
established. First experience on logistics (including equipment and training of personnel) and quality 
issues are available now from multicentre trials [232]. Finally, relevant outcome parameters defining 
the success of stem cell therapy and - potentially - its superiority vs. other therapies need to be agreed 
upon in order to compare individual approaches [233].  
Cell therapy after MI, even after optimization of cell function, engraftment and survival, might still 
meet its limit through the impotency of this therapy approach to supply sufficiently high numbers of 
structural and contractile elements. Surgical approaches aiming specifically at improving structural 
stability and contractile force -especially for the long-term prevention of heart failure -include ex vivo 
engineered patches of various biomaterials, optionally seeded with cells and/or growth factors [234, 
235]. Although still facing many difficulties on its way to clinical applications, this approach might prove 
more efficient in patients with advanced heart failure and a severe loss of contractile cardiomyocytes 
[236, 237]. The demands upon the material serving as matrix are high: it should not elicit host 
inflammatory response, feature conductance and mechanical properties similar to the host 
myocardium, and be stable over long time periods under repetitive physical strain [238]. Therefore, 
scaffold-free cell patches might constitute an alternative approach [239, 240]. Yet, long-term 
engraftment and stability issues, as well as connection to blood supply may also complicate the 
development of scaffold-free cardiac patches, so far limiting patch thickness/size [241]. Another 
obstacle to overcome for both approaches consists in ensuring proper electrical coupling of the 
transplanted patches to avoid arrhythmia, similar as discussed above for the transplantation of single-
cell suspensions [242]. Here, the maturity of the cell type, determining distinct calcium current profiles, 
is critical [216-218]. While immature cells over time integrate with their neighbour cells, the risk of 
tumour formation or calcification is increased when embryonic undifferentiated SCs are used [53, 243]. 
In contrast, electrical coupling remains problematic with pre-differentiated cardiomyocytes. It remains 
to be seen whether the ex vivo de-differentiated inducible pluripotent stem (iPS) cells offer a better 
source for the generation of autologous tissue patches [244-246]. Yet, reprogramming of cells derived 
from CVD patients might be limited by epigenetic changes and DNA damage due to their levels of 
oxidative stress. Recent pioneering studies have established that epigenetic modifications are carried 
over to  the iPS cell and that reprogramming may introduce aberrant DNA methylation, potentially 
affecting functionality and/or genetic stability of the reprogrammed cells [247, 248].  
 
  
4. SUMMARY AND CONCLUSION  
Current clinical data support a small but significant benefit of autologous cell transplantation with 
respect to cardiac function in the setting of acute myocardial infarction. However, the study outcome 
was divergent with regard to the extent of benefit, and in some cases did not support superiority of 
stem cell transplantation. Critical points to optimize in future trials are the functionality of the 
transplanted cells, milieu conditions within the recipient tissue, and rate of cell engraftment. In the 
setting of post-MI treatment, the main effect of HSC/“EPC” among the BMCs seems to consist in 
accelerating angiogenesis, thus enhancing perfusion and providing better survival conditions to 
remaining cardiac cells. Myeloid cells among the “EPC”/BMC might also modulate milieu conditions, 
such as the balance between inflammatory and repair-promoting cytokines, or nitric oxide and oxygen 
radical levels.  
Preservation of S/PC niches within the bone marrow and possibly also the modulation of their 
differentiation, function and survival can be targeted by drugs, such as statins, as well as lifestyle 
adaptation. In patients with established CVD e.g. statin treatment or physical exercise, was able to 
increase “EPC” availability within the blood and their cellular functions. Furthermore, CD34+ cell-
capturing stents combined with drug-eluting design are currently entering clinical trials, and may 
represent a novel approach to accelerate stent healing in the coronary artery.  
The safety of different cell-based treatment approaches needs to be closely monitored with respect to 
the occurrence of adverse events, such as arrythmias or cell transplantationinduced promotion of 
neointima formation.  
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Figure 1. Potential effects of “endothelial progenitor cells (EPC)” on microvascular disease: In 
conditions with high oxidative stress e.g. in diabetes or aging, microvascular cells (i.e. EC, pericytes) die 
resulting in dissociation of microvessels. Extravasating leukocytes and dysfunctional “EPC”/early 
outgrowth cells (EOC) might aggravate this process by the secretion of inflammatory mediators, such 
as cytokines or reactive oxygen species (purple). Healthy “EPC”/EOC might counteract the loss of 
endothelial cells in several ways, including secretion of pro-survival factors such as nitric oxide or 
interleukin 10 and by supporting vessel stability by attracting pericytes (blue). 
  
 Figure 2: Potential effects of “endothelial progenitor cells (EPC)” in macrovascualr disease: Functional 
“EPC”/early outgrowth cells (EOC) from healthy individuals (blue) are involved in maintaining  
endothelial integrity e.g. by paracrinally inducing nitric oxide generation or protecting endothelial cells 
(EC) from apoptosis, while dysfunctional EOC, as e.g. in diabetic patients, might also promote 
inflammatory responses via secretion of inflammatory mediators and chemoattractants (purple). SMC: 
smooth muscle cells. 
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 Table 1: Stategies for Ex Vivo Improvement of Autologous “Endothelial Progenitor Cells” (EPC) for 
Transplantation. Pre-Clinical And Clinical Results 
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